**AGENDA FOR THE 96th IRB MEETING**

Date: 18.11.24; Time: 2.00pm-4.40pm

Venue: Tata Medical Center, Board Room

|  |  |  |  |
| --- | --- | --- | --- |
| **TIME** | **TOPIC** | | |
| **2.00-2.10** | Welcome address by IRB Chairperson & approval of previous meeting minutes | | |
| **2.10-2.20** | Discussion on e-IRB Portal | | |
| **2.20-2.35** | 2024/PHARMA/154/IRB54 | Dr Dibakar Podder | A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1) |
| **2.35-2.50** | 2024/PHARMA/155/IRB55 | Dr.Tapesh Bhattacharyya | A Prospective, Randomized, Double Blind, Multicentric, Parallel Group Phase-III Clinical study to Evaluate the Efficacy, Safety and Immunogenicity of BP01 (Bevacizumab) Versus EU approved Avastin® along with chemotherapy XELOX in Metastatic colorectal cancer patients |
| **2.50-3.05** | 2024/TMC/335/IRB56 | Dr.Santam Chakraborty | Can Telemedical follow up with Integrated electronic patient reported outcomes meet the survivorship care needs for patients with gynecological cancer receiving pelvic radiotherapy:A single arm prospective cohort study(TIPS) |
| **3.05-3.20** | 2024/TMC/334/IRB57 | Dr.Santam Chakraborty | Cervical and circulating HPV DNA detection in carcinoma cervix using Isothermal Nueleie acid Amplification: determination of diagnostic accuracy and prognostic utility(HINA) |
| **3.20-3.35** | 2024/TMC/336/IRB58 | Dr.Prateek Jain | Evaluation of spatial ecology of tie-2 activated myofibroblastic-CAFs as potential prognostic indicator of Oral Cancer(GBOC TMA) |
| **3.35-3.50** | 2024/TMC/337/IRB59 | Dr.Ghara | Indian Childhood Acute Promyelocytic Leukemia Study (I-ChAMPs) |
| **3.50-4.05** | 2024/TMC/338/IRB60 | Dr Angshuman Rudra Pal | External oblique  intercostal block vs Oblique subcostal transversus abdominis plane block for postoperative pain  management in surgeries with modified Makuuchi incision- A Randomised Controlled Study |
| **4.05-4.20** | 2024/TMC/339/IRB61 | Dr. Shikhar More | Optimal Sedation Analgesia In Upper  Gastrointestinal Endoscopic Interventions: Determination and Comparison of Median Effective Target  Concentration of Propofol in Combination With Fentanyl versus Remifentanil |
| **4.20-4.35** | Amendments + PD/ PVs + SAEs + Waiver | | |
| **4.35-4.40** | Other Discussion | | |